A Phase 1/2 Study to Evaluate MEDI4736

Clinical Trial ID NCT01693562

PubWeight™ 40.18‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01693562

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
2 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
3 Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int 2015 1.25
4 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
5 Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Sci Rep 2015 1.18
6 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
7 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
8 Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol 2016 1.12
9 Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol 2015 1.10
10 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
11 Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 2016 1.03
12 New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 2015 1.02
13 Advances in immunotherapy for treatment of lung cancer. Cancer Biol Med 2015 0.95
14 Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res 2015 0.94
15 The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016 0.93
16 From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer 2016 0.90
17 Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial. Eur J Cancer 2016 0.90
18 Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol 2015 0.89
19 Immune checkpoint blockade: the hope for immunotherapy as a treatment of lung cancer? Semin Oncol 2013 0.87
20 Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagn Pathol 2016 0.84
21 The tumor microenvironment in esophageal cancer. Oncogene 2016 0.83
22 Current progress in immunotherapy for pancreatic cancer. Cancer Lett 2015 0.83
23 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
24 Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. Onco Targets Ther 2016 0.81
25 Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy. Expert Opin Ther Targets 2015 0.81
26 Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol 2015 0.81
27 Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol 2016 0.81
28 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
29 Immunotherapy in lung cancer. Transl Lung Cancer Res 2014 0.80
30 Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. Transl Lung Cancer Res 2015 0.80
31 Cellular and molecular biology of small cell lung cancer: an overview. Transl Lung Cancer Res 2016 0.79
32 Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016 0.79
33 Shedding light on the molecular determinants of response to anti-PD-1 therapy. Transl Lung Cancer Res 2015 0.79
34 Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect. J Immunol Res 2015 0.78
35 Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett 2015 0.78
36 Immune checkpoint blockade therapy for bladder cancer treatment. Investig Clin Urol 2016 0.78
37 Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer. Therap Adv Gastroenterol 2016 0.78
38 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
39 Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions. BioDrugs 2014 0.76
40 Colorectal clinical trials: what is on the horizon? Future Oncol 2016 0.75
41 Current clinical immunotherapeutic approaches for head and neck cancer. F1000Res 2016 0.75
42 Novel therapy for advanced gastric cancer. World J Gastrointest Oncol 2015 0.75
43 Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World J Gastroenterol 2016 0.75
44 Clinical Trials Corner. Bladder Cancer 2016 0.75
45 Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. Onco Targets Ther 2016 0.75
Next 100